title: Corneal collagen cross-linking for Terrien marginal degeneration.
abstract: OBJECTIVE
  To report the long-term clinical outcome of a patient diagnosed as having Terrien marginal degeneration (TMD) who was subjected to corneal collagen cross-linking (CXL) with ultraviolet-A and riboflavin in both eyes.
  
  
  METHODS
  Topographical changes were assessed by high-resolution Scheimpflug imaging and anterior segment optical coherence tomography. Eccentric epithelium-off CXL was performed in both eyes while protecting the corneal limbus. Irradiation was performed with a fluence of 5.4 J/cm(2), using 3 mW/cm(2) for 30 minutes.
  
  
  RESULTS
  Five years of postoperative follow-up showed regression of the keratometric values, a local thickening of the corneal stroma, and bilateral improvement of corrected distance visual acuity.
  
  
  CONCLUSIONS
  CXL may arrest progression in TMD and even reverse the catabolic process in the corneal stroma. CXL might represent an alternative therapeutic approach for the management of TMD.
authors.forename: Farhad
authors.initials: F
authors.lastname: Hafezi
authors.forename: Zisis
authors.initials: Z
authors.lastname: Gatzioufas
authors.forename: Theo G
authors.initials: TG
authors.lastname: Seiler
authors.forename: Theo
authors.initials: T
authors.lastname: Seiler
mesh_terms: D003094:Collagen / Q000378:metabolism*; D003317:Corneal Dystrophies, Hereditary / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D003319:Corneal Stroma / Q000378:metabolism* / Q000473:pathology; D019781:Corneal Topography; D003432:Cross-Linking Reagents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D012256:Riboflavin / Q000627:therapeutic use*; D016896:Treatment Outcome; D014466:Ultraviolet Rays; D014792:Visual Acuity / Q000502:physiology
chemical_list: D003432:Cross-Linking Reagents; D017319:Photosensitizing Agents; D003094:Collagen; D012256:Riboflavin